Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2016 | The management of transaminitis in patients receiving idelalisib

William Wierda • 3 Jun 2016
ASCO 2016
Chronic Lymphocytic Leukemia Idelalisib

William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX gives an overview of his poster on the ‘Management of transaminase elevations in patients receiving idelalisib’ in chronic lymphocytic leukemia (CLL) presented at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. According to Dr Wierda, transaminitis can be seen in patients who are initiating on idelalisib after approximately 2-4 weeks and is usually reversible. The management of this side effect is important in order to avoid damage to the liver.

More from William Wierda

1:12
Primary analysis of TRANSCEND-CLL-004: liso-cel in R/R CLL
William Wierda • 10 Jun 2023
2:08
Disease characteristics impacting treatment decisions in CLL
William Wierda • 10 Jun 2023
2:20
Genomic evolution and resistance to pirtobrutinib in CLL: insights from the BRUIN study
William Wierda • 10 Jun 2023
1:07
The current status of liso-cel in CLL and updates from the TRANSCEND-CLL-004 trial
William Wierda • 28 Sep 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals